This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutInfliximabWhat is infliximabInflammatory Bowel DiseaseMaximising patient outcomes with IBDBiosimilarsWhat is a biosimilarFuture of biosimilarsBiologic switchingINFLECTRA® Introducing INFLECTRA® Position statementsECCOEULARESPGHANDosing & safetyDosingIV dosingAdministration & storageAdministrationStorageSafety informationImportant safety informationConsiderations for SwitchingSwitching to InflectraSafety informationImportant safety informationSafety informationSafety informationClinical evidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceReal-world experienceSummary: real-world evidenceSupporting ResourcesVideosMaterialsPatient Support


Inflectra®(infliximab) Prescribing Information. Adverse events reporting information can be found at the bottom of the page.

 

Patient Support

Therapeutic Drug Monitoring (TDM) and biomarkers such as faecal calprotection (FC) can be useful tools in helping to support clinical decision making to optimise treatment. Treatment optimisation can involve changing the dosing, infusion interval or stopping treatment. 

Please note that Inflectra/infliximab is not licensed for dose escalation in ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, paediatric ulcerative colitis or paediatric Crohn's disease. Inflectra/infliximab is licensed for dose escalation in rheumatoid arthritis and crohn's disease
 

Therapeutic Drug Monitoring (TDM)

TDM is a measurement of serum drug concentrations and anti-drug antibodies (ADA) to allow more accurate adjustments of drug levels in an indiviudal patient.1-3

Figure adapted from Tracy D, et al. 2008.

Watch Dr Walter Reinisch discuss the benefits of using TDM in clinical practice:TDM can provide clinical insights in either:
  • Primary non-response (PNR): lack of improvement in clinical signs and symptoms with induction therapy4
  • Secondary loss of response (LOR): loss of response during maintenance treatment after initial response to induction therapy4
Why are infliximab trough levels and ADA measured for TDM in IBD?Monitoring of infliximab trough levels is associated with improved clinical outcomes during induction therapy and maintenance therapy.5,6  Detectable ADA is associated with decreased serum concentration of infliximab7-9 and understanding ADA status is important to inform clinical decision making in induction and maintenance therapy.7,10,11Applying TDM in clinical practiceEven minimal information can inform treatment strategy . The simple algorithm below can be used to interpret TDM results in clinical practice.18,19 What is Faecal Calprotectin (FCT)

Faecal calprotectin (FC) is a biomarker of disease activity in IBD.

FC correlates with inflammatory activity in CD and UC.1 

It is stable in stool for up to 3 days at room temperature so it is readily mesaurable.2 

FC levels can be used to:

  • Confirm active disease (when clinical symptoms are present)
  • Evaluate efficacy of current thearpy (mucosal healing)
  • Predict disease course
  • Stratify treatment (modulating disease course)

Return to our Inflectra homepage to explore more about Infliximab 

Remicade™ is a registered trademark of MSD.CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.References:Colombel J-F, et al. Inflamm Bowel Dis 2012. 18:349–358Kingsley M, et al. Gastroenterol Hepatol 2016. 12:308–315Tracey D, et al. Pharmacol Ther 2008. 117:244–279Sprakes MB, et al. J Crohns Colitis 2012. 6:143–153Adedokun O, et al. Gastroenterology 2014. 147:1296–1307Bortlik M, et al. J Crohns Colitis 2013. 7:736–743Ungar B, et al. Gut 2014. 63:1258–1264Kingsley M, et al. Gastroenterol Hepatol 2016. 12:308–315Vermeire S, et al. Gut. 2007. 56:1226–1231Roda G, et al. Clin Trans Gastroenterol 2016. 7:e13Golovics PA, et al. J Crohns Colitis 2017. 11:S4, ECCO abstract OP003Steenholdt C, et al. Gut 2014. 63:919–927.Steenholdt C, et al. Gut 2014. 63:919–927Roblin X, et al. Journal of Market Access & Health Policy 2015. 3:292–29Ding NS, et al. Aliment Pharmacol Ther 2016. 43:30-51Velayos FS and Sandborn WJ. Curr Gastroenterol Hepatol 2007. 9:521–527Pouillon L, et al. J Crohns Colitis 2017. 11:S4, ECCO abstract OP006Khanna R, et al. Aliment Pharmacol Ther 2013. 38:447–459Bendtzen K, et al. Scand J Gastroenterol 2009. 44:774–781
Resources
Browse additional content and information that may be of interest to you  Explore MoreLoading
PP-IFA-GBR-0621. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​